Molecular Hydrogen for Outpatients with COVID-19 (Hydro-COVID): A Phase 3 Randomised, Triple-Blinded, Pragmatic, Placebo-Controlled, Multicentre Trial.
Yoann Gaboreau, Aleksandra Milovančev, Carole Rolland, Claire Eychenne, Jean-Pierre Alcaraz, Cordelia Ihl, Roseline Mazet, François Boucher, Celine Vermorel, Sergej M Ostojic, Jean-Christian Borel, Philippe Cinquin, Jean-Luc Bosson · Journal of clinical medicine · 2024
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 5 patients, HRW was not superior to placebo in preventing clinical worsening at day 14: in the H₂ group, 46.1% in the H₂ group, 43.5% in the placebo group, hazard ratio 1.09, 90% confidence interval [0.90-1.31].
What the Researchers Studied
5 patients
How the Study Was Conducted
Randomized, placebo-controlled human clinical trial.
How Molecular Hydrogen Was Used
Hydrogen-rich water
What the Researchers Found
HRW was not superior to placebo in preventing clinical worsening at day 14: in the H₂ group, 46.1% in the H₂ group, 43.5% in the placebo group, hazard ratio 1.09, 90% confidence interval [0.90-1.31].